Список проголосовавших за комментарий " On The Wires<ul><li>Effective February 9, 2017, STERIS plc (<strong>STE</strong>) completed the divestiture of Synergy Health Textiel Service B.V. and its subsidiaries, STERIS's remaining linen business, with a buy-out by that business's current management team. Terms of the transaction have not been disclosed. STERIS's fiscal 2017 revenues will be reduced by approximately $14 million as a result of this transaction with no impact on profitability.</li><li>Hannon Armstrong Sustainable Infrastructure Capital (<strong>HASI</strong>) announced a $144 million investment to acquire over 4,000 acres of land that is leased under long-term contracts to over 20 individual solar projects with investment grade off-takers. The projects have an aggregate capacity of over 690 megawatts direct current.</li><li>RAVE Restaurant Group (<strong>RAVE</strong>) today announced that it has extended the shareholder rights offering for up to $3,000,000 of its 4% Convertible Senior Notes due 2022 from the previous expiration date of February 13, 2017, until 5:00 p.m., Dallas, Texas time, on Friday, February 24, 2017. Shareholders desiring to exercise.</li><li>Sundance Energy (<strong>SNDE</strong>) reports proved reserves as December 31, 2016 of 33.8 MMboe, +29% Y/Y.Proved undeveloped reserves increased by 37% to 20.5 MMboe as of December 31, 2016 reflecting continued development of Sundance's acreage. Sundance's proved reserves were 39% proved developed producing and 79% liquids (61% oil). Proved reserves revisions, extensions, discoveries and other additions of 8.3 MMboe during the year equate to a reserve replacement ratio of ~358%. Sundance's finding & development cost (F&D) for proved developed producing reserves was $12.31 per barrel of oil equivalent (boe) for the year ended December 31, 2016.</li><li>On February 8, 2017, Acorda Therapeutics (<strong>ACOR</strong>) entered into a settlement agreement with Apotex Corporation and Apotex to resolve pending patent litigation brought by the Company against Apotex involving Ampyra (dalfampridine) Extended-Release Tablets. The pending patent litigation was filed by the Company in the U.S. District Court for the District of Delaware in response to Apotex's submission of an Abbreviated New Drug Application to the FDA, seeking marketing approval for a generic version of Ampyra. As a result of the settlement agreement, Apotex will be permitted to market a generic version of Ampyra in the United States at a specified date in 2025, or potentially earlier under certain circumstances. Details of the settlement are confidential, and the parties will submit the agreement to the Federal Trade Commission and the Department of Justice, as required by federal law.</li></ul>"